research Site of Beige and Leaden Pigment Gene Expression Determined by Recombinant Embryonic Skin Grafts and Aggregation Mouse Chimaeras Employing Sash Homozygotes
Beige and leaden pigment genes act within melanocytes, affecting pigment patterns.
Search
forLearn
0 / 0 results — no results
Research
5 / 1000+ results 
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Colon Cancer Stem Cells: Promise of Targeted Therapy
Targeting colon cancer stem cells might lead to better treatment results.
research Stem Cells in the Body
Stem cells regenerate tissues and their behavior varies by environment, suggesting the hematopoietic system model may need revision.
research The Mouse Hairy Ears Mutation Exhibits an Extended Growth (Anagen) Phase in Hair Follicles and Altered Hoxc Gene Expression in the Ears
The mouse hairy ears mutation causes longer ear hair due to changes in gene expression.
Community Join
3 / 3 resultscommunity Effect of dutasteride 0.5 mg/d in men who don't respond to finasteride (study)
Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.
community Back again with a 17 month update. (Fin/Min doing the heavy lifting, occasional 0.5mm microneedling, and Nizoral for scalp health) - Angles are not identical but whatever - Expecting and hoping to be back to pre-hairloss hairline within 6 months from now.
The conversation is about a user's 17-month progress in treating hair loss using finasteride, minoxidil, occasional 0.5mm microneedling, and Nizoral. The user reports significant hairline recovery and aims to achieve a pre-hair loss hairline within the next 6 months.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.